statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wednesday’s Wall Street initiations have put the spotlight on three stocks from different sectors, with analysts issuing optimistic ratings. However, retail investor sentiment on Stocktwits tells a different story. Let’s dive into the details.Imax (IMAX): Riding A Theatrical Rebound WaveSeaport Research initiated coverage of Imax with a Buy rating and a $23 price target, highlighting a near-term opportunity as the film industry’s theatrical release schedule normalizes. The firm said the stock benefits from the film industry’s recovery post-COVID-19 and an increasing market share for premium screens. Recent bullish sentiment on Stocktwits (72/100) is driven by high message volumes ahead of IMAX’s Q2 results, set to be released tomorrow.<figure class="image"><img style="aspect-ratio:1324/314;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/IMAX_Stocktwits_sentiment_Jul_24_2f9fad8e71.png" alt="IMAX Stocktwits sentiment Jul 24.png" width="1324" height="314"><figcaption>IMAX Stocktwits sentiment Jul 24</figcaption></figure>Key recent developments include a partnership with muvi Cinemas in Saudi Arabia, expanding IMAX’s footprint in the region. Additionally, analyst Eric Wold from B. Riley Securities has increased box office projections for several major films, including “Despicable Me 4” (from $260 million to $315 million), “Inside Out 2” (from $305 million to $625 million), and “Deadpool &amp; Wolverine” (from $365 million to $475 million), further boosting confidence in IMAX’s potential.JFrog (FROG): Cloud Growth and Leadership ChangesTD Cowen initiated coverage of JFrog with a Buy rating and a $50 price target, citing the company’s strong cloud growth prospects. Despite this positive outlook, Stocktwits sentiment remains bearish at 35/100, reflecting cautious retail investor attitudes following an unimpressive earnings report in May. Shares are down nearly 1.9%, trading at $37.92, although they are up over 13% year-to-date.<figure class="image"><img style="aspect-ratio:1326/316;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/FROG_Stocktwits_sentiment_Jul_24_8f4ebea448.png" alt="FROG Stocktwits sentiment Jul 24.png" width="1326" height="316"><figcaption>FROG Stocktwits sentiment Jul 24</figcaption></figure>Recent news includes the appointment of Unity CFO Luis Felipe Visoso to JFrog’s Board of Directors, which is expected to drive growth in JFrog’s DevOps, DevSecOps, and AI/MLOps markets. Investors are now looking ahead to the company’s Q2 financial results, scheduled for release after the bell on August 7th.Biohaven (BHVN): Biotech Potential Amid Bearish SentimentMorgan Stanley initiated coverage of Biohaven with an Overweight rating and a $58 price target, citing the company’s broad pipeline across multiple disease areas as a unique value driver among smid-cap biotech firms. Despite this, Stocktwits sentiment has hit its lowest in a year at 6/100, with message volumes reaching nearly 2-month highs.<figure class="image"><img style="aspect-ratio:1326/316;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/BHVN_Stocktwits_sentiment_Jul_24_98594ced17.png" alt="BHVN Stocktwits sentiment Jul 24.png" width="1326" height="316"><figcaption>BHVN Stocktwits sentiment Jul 24</figcaption></figure>The stock has faced pressure since late May on underwhelming interim data from a Phase 1 study of BHV-1300, Biohaven’s lead investigational drug, which fell short of investor expectations with a 30-37% reduction in Immunoglobulin G (IgG) levels. However, William Blair analysts noted that future doses could achieve greater IgG reductions, while investors also took some positive cues from director John W. Childs recently acquiring 28,400 shares.<a href="https://www.vecteezy.com/photo/1227265-investor-analyzing-graphs">Photo</a> via Vecteezy

IMAX, JFrog, Biohaven Lead Top Wall Street Initiations Today: Are Retail Traders Buying In?

Wall Street sees bright prospects for IMAX and JFrog, but Biohaven faces investor skepticism despite analyst optimism.

Equity

Biohaven Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas including Immunology, Neuroscience, Metabolic Disorders and Oncology at Annual Investor R&D Day

Biohaven Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas including Immunology, Neuroscience, Metabolic Disorders and Oncology at Annual Investor R&D Day...

Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors

Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors Biohaven Doses First Patient with its Novel Trop-2...

Biohaven Reports First Quarter 2024 Financial Results and Recent Business Developments

Biohaven Reports First Quarter 2024 Financial Results and Recent Business Developments Biohaven Reports First Quarter 2024 Financial Results and Recent Business Developments PR Newswire NEW HAVEN...

Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares Biohaven Announces Closing of Public Offering and Full Exercise of the...

Biohaven Announces Pricing of $230 Million Public Offering of Common Shares

Biohaven Announces Pricing of $230 Million Public Offering of Common Shares Biohaven Announces Pricing of $230 Million Public Offering of Common Shares PR Newswire NEW HAVEN, Conn., April 18, 2024...

Biohaven Announces Proposed Public Offering of Common Shares

Biohaven Announces Proposed Public Offering of Common Shares Biohaven Announces Proposed Public Offering of Common Shares PR Newswire NEW HAVEN, Conn., April 17, 2024 NEW HAVEN, Conn., April 17, 2024...

Biohaven Showcases Innovative Neuroscience Portfolio with 20 Presentations at the 2024 American Academy of Neurology (AAN) Annual Meeting and Provides Other Business Updates

Biohaven Showcases Innovative Neuroscience Portfolio with 20 Presentations at the 2024 American Academy of Neurology (AAN) Annual Meeting and Provides Other Business Updates Biohaven Showcases...

Biohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Developments

Biohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Developments Biohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business...

Biohaven Highlights Progress Across Innovative Portfolio and Outlines 2024 Anticipated Milestones at the 42nd Annual J.P. Morgan Healthcare Conference; Established Extensive Portfolio Across 20 Therapeutic Indications in Neuroscience, Immunology and Oncol

Biohaven Highlights Progress Across Innovative Portfolio and Outlines 2024 Anticipated Milestones at the 42nd Annual J.P. Morgan Healthcare Conference; Established Extensive Portfolio Across 20...

Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.

Volume	870,936.00
52-Wk High	$62.21
52-Wk Low	$16.45

BHVN Biohaven Pharmaceutical Holding Company Ltd

About

Feed

News

Sentiment

Earnings

Fundamentals